Bortezomib Adco 3,5 mg Powder for solution for injection
PDF Leaflet Revision Date: 30 August 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multiple myeloma and mantle cell lymphoma.
Dosage (summary)
1.3 mg/mu00b2 twice weekly for 2 weeks, followed by a 10-day rest.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; effective contraception required during treatment and for several months after.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Oral hypoglycemics
Contraindications
- Hypersensitivity
- Acute diffuse infiltrative pulmonary disease
Common side effects
- Nausea
- Diarrhoea
- Thrombocytopenia
- Peripheral neuropathy
Counselling Points
- Avoid pregnancy during treatment
- Use effective contraception
- Monitor for signs of neuropathy
Serious warnings
- Inadvertent intrathecal administration may be fatal
- Monitor for cardiac failure
Important Disclaimer
The Bortezomib Adco 3,5 mg Powder for solution for injection professional information leaflet below is the property of Adcock Ingram Critical Care and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
